Poxel SA

7PO

Company Profile

  • Business description

    Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

  • Contact

    259/261 Avenue Jean Jaures
    Immeuble le Sunway
    Lyon69007
    FRA

    T: +33 437372010

    https://www.poxel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    6

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,757.9013.20-0.15%
CAC 407,656.1227.61-0.36%
DAX 4023,317.81116.84-0.50%
Dow JONES (US)42,171.6644.14-0.10%
FTSE 1008,843.479.440.11%
HKSE23,710.69269.61-1.12%
NASDAQ19,546.2725.180.13%
Nikkei 22538,885.15348.410.90%
NZX 50 Index12,627.3212.03-0.10%
S&P 5005,980.871.85-0.03%
S&P/ASX 2008,531.2010.10-0.12%
SSE Composite Index3,388.811.400.04%

Market Movers